Abstract | BACKGROUND AND OBJECTIVES: The recipients of liver transplantation (LT) are subjected to lifelong immunosuppression with its many drawbacks. De novo and recurrent malignancy in transplant recipients are attributed to attenuation of immunosurveillance. In the present study, we present our experience with de novo malignancies encountered after both deceased and living donor liver transplantations. DESIGN AND SETTING: Retrospective study of patients referred to LT center between April 2001 and January 2010. PATIENTS AND METHODS: Various data were collected including type of malignancy and histopathologic features, immunosuppression regimen, and patient survival. RESULTS: CONCLUSION: EBV-associated PTLD is the most frequently encountered de novo malignancy after LT and is easily treatable by chemotherapy and reduction of immunosuppression.
|
Authors | Bassem Hegab, Hatem Khalaf, Naglaa Allam, Ayman Azzam, Faisal Aba Al Khail, Waleed Al-hamoudi, Yasser Kamel, Hamad Al Bahili, Mohammed Al Sofayan, Mohammed Al-Sebayel |
Journal | Annals of Saudi medicine
(Ann Saudi Med)
2012 Jul-Aug
Vol. 32
Issue 4
Pg. 355-8
ISSN: 0975-4466 [Electronic] Saudi Arabia |
PMID | 22705604
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antigens, CD20
- Immunosuppressive Agents
|
Topics |
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Antigens, CD20
(immunology)
- Child
- Child, Preschool
- Epstein-Barr Virus Infections
(etiology)
- Female
- Humans
- Immunosuppression Therapy
(adverse effects)
- Immunosuppressive Agents
(administration & dosage, adverse effects, therapeutic use)
- Infant
- Liver Transplantation
(methods)
- Lymphoproliferative Disorders
(etiology)
- Male
- Middle Aged
- Neoplasms
(epidemiology, etiology, pathology)
- Retrospective Studies
- Survival Rate
- Young Adult
|